PROTACs for BRDs proteins in cancer therapy: a review

Figures & data

Figure 1. PROTAC-mediated degradation of target proteins through the UPS.

Figure 2. (A) Structure of the human BRDs of transcriptional coactivator CREB-binding protein CREBBP (PDB: 5NU3). The KAc binding site is blocked by the inhibitor XDM-CBP (shown in yellow)^27,58. (B) Phylogenetic tree of the human BRDs family. The green branches represent proteins such as BRD2, BRD3, BRD4, etc. The purple branches represent proteins such as BRD1, BRD7, and BRD9⁵⁹.

Figure 3. Representative BRDs inhibitors.

Figure 4. Representative PROTACs targeting BRD4.

Figure 5. Representative PROTACs targeting BRD2/3/4.

Figure 6. Representative PROTACs targeting BRD9.

Figure 7. Representative PROTACs targeting BRD4.

Figure 8. Representative PROTACs targeting BRD4.

Figure 9. Representative PROTACs targeting BRD2/3/4.

Figure 10. Representative PROTACs targeting BRD2/4.

Figure 11. Representative PROTACs targeting BRD7/9.

Pervaiz M, Mishra P, Günther S. Bromodomain drug discovery - the past, the present, and the future. Chem Rec 2018;18:1808–17.

 PubMed Web of Science ®Google Scholar

Hugle M, Lucas X, Ostrovskyi D, et al. Beyond the BET family: targeting CBP/p300 with 4-acyl pyrroles. Angew Chem Int Ed Engl 2017;56:12476–80.

 PubMed Web of Science ®Google Scholar

Liu L, Zhen XT, Denton E, et al. ChromoHub: a data hub for navigators of chromatin-mediated signalling. Bioinformatics 2012;28:2205–6.

 PubMed Web of Science ®Google Scholar